T300A polymorphism of ATG16L1 and susceptibility to inflammatory bowel diseases:A meta-analysis

AIM:To evaluate the association of the autophagy- related 16-like 1 (ATG16L1 ) T300A polymorphism (rs2241880) with predisposition to inflammatory bowel diseases (IBD) by means of meta-analysis.METHODS: Publications addressing the relationship between rs2241880/T300A polymorphism of ATG16L1 and Crohn‘s disease (CD) and ulcerative colitis (UC) were selected from the MEDLINE and EMBASE data-bases. To make direct comparisons between the data collected in these studies, the individual authors were contacted when...     

ATG16L1基因启动子单核苷酸多态性可增加急性心肌梗死的易感性

目的 探讨ATG16L1基因启动子序列单核苷酸多态性(SNP)与急性心肌梗死(AMI)的相关性。方法采用病例-对照研究方法,对285例AMI患者和296例对照人群的ATG16L1基因启动子采用聚合酶链反应扩增片段并测序,结合DNA测序后的序列及比对SNP数据库后进行数据统计和分析。运用Hardy-Weinberg平衡检验后,应用χ²检验和t检验进行相关分析。采用Logistic回归对多种危险因素以及3个SNP位点与AMI易感性进行关联性分析。用Haploview 4.2软件和SHEsis在线软件进行连锁不平衡及单倍型分析。TRANSFAC数据库用于预测可能受SNP影响的转录因子的结合位点。结果 多因素Logistic回归分析结果显示男性、吸烟史、高血压是AMI的独立危险因素(P＜0.05),而高密度脂蛋白胆固醇是AMI的保护因素(P＜0.05)。在ATG16L1基因启动子序列中的3个SNP(rs1816753、rs12476635、rs2289477)中,rs1816753的TC基因型与AMI间存在关联,可明显增加AMI的患病风险(OR=2.519,95%CI:1.130～5.615,P＝0.024)。通过Haploview 4.2软件分析显示3个SNP之间呈强连锁。结论 ATG16L1基因启动子SNP可能与AMI易感性相关,rs1816753的TC基因型可能是AMI的遗传危险因素。     

The Ala45Thr polymorphism of BETA2/NeuroD1 gene and susceptibility to type 1 diabetes mellitus in caucasians.

It has recently been shown that mutations in BETA2/NeuroD1 are responsible for the development of type 2 diabetes mellitus (T2DM) in Caucasians. This gene is located near the IDDM7 region and one of its amino acid polymorphisms, Ala45Thr, has been associated with type 1 diabetes (T1DM) in Japanese and Danish populations. The aim of our study is to examine Ala45Thr for its role in T1DM in Caucasians. We used both population-based case-control analysis and family-based transmission/disequilibrium testing (TDT). Genotyping was carried out by the dot-blotting method using P32. Study subjects comprised 202 type 1 diabetes cases (mean age at diagnosis: 11.1 years, mean age at examination: 36.4 years) and 139 controls with normal fasting glucose. For the TDT study, allelic transmission was evaluated in 209 case family trios. The frequency of the Ala45 allele was 70.3 % in cases and 62.9 % in controls (p=0.04), and 47.5 % of cases were Ala45 homozygotes compared to 36.0 % of controls (p=0.03). The TDT component of the study did not achieve statistical significance. However, given the high frequency of this variant even among controls, exceptionally large data sets are needed to provide adequate power for this approach. Our case-control study suggests that the Ala45 variant of BETA2/NeuroD1 may be associated with T1DM in Caucasians (or in linkage disequilibrium with a causative variant). However, this finding should be confirmed by a much larger family-based study.     

神经分化因子1 (Ala45Thr)基因多态性与2型糖尿病易感性关系的meta分析

目的 通过meta分析评估神经分化因子1(Neuro1D1)Ala45Thr基因多态性与2型糖尿病的关联性.方法 通过系统检索PubMed、EMBASE、CNKI、万方数据库、维普数据库等中英文数据库,在Kavvoura等已发表1999年至2004年NeuroD1 (Ala45Thr)基因多态性与2型糖尿病关联性的meta分析基础上,纳入2004年至2012年有关NeuroD1 (Ala45Thr)基因多态性与2型糖尿病相关性的研究,以2型糖尿病组和正常对照组基因分布的OR值为统计量,应用Rev Man 5.0软件对研究结果进行异质性检验和相关数据的合并,最终纳入13篇病例对照试验文献.结果 共入选2型糖尿病患者3 896例,对照组3 186名.Meta分析结果显示,黄种人2型糖尿病与对照组Thr45Thr45/(Ala45Thr+Ala45Ala45) OR值为3.16(95％CI0.99 ～10.11),白种人OR值为1.09(95％ CI0.90～ 1.32),差异均无统计学意义(P＞0.05) 而2型糖尿病组和对照组G/A等位基因频率OR值为0.85(95％ CI0.72 ～0.99)/1.18(95％ CI.07 ～ 1.38),差异有统计学意义(Z=2.02,P=0.04).结论 NeuroD1 (Ala45Thr)位点A等位基因可能是2型糖尿病的危险因素.     

Meta-analysis on the effect of the Ala54Thr polymorphism of the fatty acid-binding protein 2 gene on body mass index

Background and aim

The results from studies published on the association of fatty acid-binding protein 2 (FABP2) Ala54Thr polymorphism with body mass index (BMI) are conflicting. In this meta-analysis, we investigated the association of the FABP2 Ala54Thr polymorphism with BMI.

Methods and results

We searched for articles published prior to June 2009 using PubMed, HugeNavigator and China National Knowledge Internet. The languages were limited to English and Chinese. Data on BMI were collected. A pooled weighted mean difference (WMD), together with 95% confidence interval (CI), was used for this meta-analysis.A total of 27 studies with 10 974 subjects were included in this meta-analysis. The pooled effect for dominant, recessive and co-dominant model comparisons did not suggest the significant association between the FABP2 Ala54Thr polymorphism and BMI in overall populations: WMD_{fixed effects} = −0.00, 95% CI: (−0.16 to 0.15), p = 0.99, WMD_{random effects} = −0.00, 95% CI: (−0.16 to 0.15), p = 0.99, p_Q = 0.77, I² = 0%, WMD_{fixed effects} = −0.12, 95% CI: (−0.39 to 0.14), p = 0.35, WMD_{random effects} = −0.12, 95% CI: (−0.39 to 0.14), p = 0.35, p_Q = 0.47, I² = 0% and WMD_{fixed effects} = 0.07, 95% CI: (−0.11 to 0.25), p = 0.45, WMD_{random effects} = 0.07, 95% CI: (−0.11 to 0.25), p = 0.45, p_Q = 0.90, I² = 0%, respectively. The results from the comparisons of ThrThr versus AlaAla and AlaThr versus AlaAla showed no evidence that the FABP2 Ala54Thr polymorphism is significantly associated with BMI in overall populations (p > 0.05). All the results from the subgroup analyses for these genetic models comparisons were not significant (p > 0.05).

Conclusions

Our meta-analysis does not support the association between the FABP2 Ala54Thr polymorphism and BMI.     

The interferon-induced helicase IFIH1 Ala946Thr polymorphism is associated with type 1 diabetes in both the high-incidence Finnish and the medium-incidence Hungarian populations

Aims/hypothesis

The rs1990760 polymorphism (Ala946Thr) of interferon induced with helicase C domain 1 (IFIH1) has been proposed to associate with type 1 diabetes. In this study, association between IFIH1 Ala946Thr and type 1 diabetes was investigated in two distinct white populations, the Hungarians and Finns.

Methods

The rs1990760 polymorphism was genotyped in 757/509 Hungarian/Finnish childhood-onset cases, 499/250 Hungarian/Finnish control individuals and in 529/924 Hungarian/Finnish nuclear family trios. Disease association was tested using case–control and family-based approaches. A meta-analysis of data from 9,546 cases and 11,000 controls was also performed.

Results

In the Hungarian dataset, the A allele was significantly more frequent among cases than among controls (OR 1.29, 95% CI 1.10–1.52; p?=?0.002). Combined analysis of Hungarian and Finnish datasets revealed a strong disease association (OR 1.235, 95% CI 1.083–1.408; p?=?0.002). Furthermore, the A allele was significantly overtransmitted in both family trio datasets (p?=?0.017 in Hungarians; p?=?0.007 in Finns). The A allele was increased in Hungarian vs Finnish cases (64.9% vs 60.8% in Finns; p?=?0.003). The meta-analysis yielded a significant effect for IFIH1 rs1990760 A allele on type 1 diabetes risk (OR 1.176, 95% CI 1.130–1.225; p?=?5.3?×?10^?15) with significant heterogeneity between effect sizes across the studied populations (p?=?0.023).

Conclusions/interpretation

This study represents the first independent confirmation of the association between type 1 diabetes and the IFIH1 gene in Hungarian and Finnish populations. Summarising the data published so far, a clear association between the Ala946Thr polymorphism and type 1 diabetes was detected, with an apparent difference in the contribution to disease susceptibility in different populations of European ancestry.     

SEL1L microsatellite polymorphism in Japanese patients with autoimmune thyroid diseases.

The autoimmune thyroid diseases (AITDs), comprising Graves' disease (GD) and Hashimoto's thyroiditis (HT), appear to develop as a result of complex interactions between predisposing genes and environmental triggers. A recently performed genome-wide linkage study identified six loci that showed evidence for linkage to AITD. One locus, GD-1, on chromosome 14q31 was mapped to within 2 centimorgans (cM) of the recently reported multinodular goiter (MNG)-1 locus. Furthermore, microsatellite markers for the thyroid stimulating hormone receptor gene on chromosome 14q31 were associated with AITDs in the Japanese population. A newly isolated growth factor, SEL1L, was recently mapped to 14q31, and we considered it an interesting candidate gene to examine with respect to both GD and MNG. We therefore have analyzed a dinucleotide (CA)n repeat polymorphism in the intron 20 of the SEL1L gene in patients with AITDs and in normal subjects. The polymorphic marker was analyzed by polymerase chain reaction (PCR) followed by electrophoresis on denaturing polyacrylamide gels. There was no significant difference in the distributions of SEL1L alleles between patients and controls. The present results do not support an association between a dinucleotide repeat polymorphism in intron 20 of the SEL1L gene and AITD in Japanese women.     

α-纤维蛋白原基因Thr312Ala多态性与脑血栓形成的关联性研究

目的探讨 α-纤维蛋白原基因Thr312Ala多态性及其与脑血栓形成之间是否存在关联性。方法 153例脑血栓形成患者(脑梗死组)和年龄、性别相匹配的158例内科住院患者及健康体检者(对照组),采用聚合酶链反应-限制性片断长度多态性检测Thr312Ala多态性,用Stadtmanl改良法和磁珠法测定其血浆胆固醇及纤维蛋白原(FIB)的水平,并分析基因多态性、血浆胆固醇水平、FIB水平和脑血栓形成之间的关联性。结果 1等位基因和1/1基因型在脑梗死组中的分布水平明显低于对照组;1等位基因与脑梗死有显著的负相关;2等位基因与脑梗死有显著的正相关;脑梗死组的胆固醇和FIB水平均显著高于对照组。Ihr312Ala基因型分层,1/1型和1/2型的脑梗死患者血浆胆固醇水平显著高于对照组;2/2型脑梗死患者血浆FIB水平显著高于对照组。结论α-纤维蛋白原基因Thr312Ala多态位点的1等位基因可能对抑制脑梗死的形成起到积极作用,这种作用可能通过影响血浆FIB水平的途径来实现的。2等位基因关联于脑血栓形成。     

Thr92Ala polymorphism in the type 2 deiodinase is not associated with T4 dose in athyroid patients or patients with Hashimoto thyroiditis

Objective  The type 2 deiodinase (D2)-Thr92Ala polymorphism has been associated with decreased D2 activity in some in vitro experiments but not in others. So far no association between the D2-Thr92Ala polymorphism and serum thyroid hormone levels has been observed in humans, but in a recent study in athyroid patients, it was suggested that patients homozygous for the Ala⁹² allele needed higher T4 doses to achieve TSH suppression.
We studied the association between the D2-Thr92Ala polymorphism with thyroid hormone levels and T4 dosage, in patients treated for differentiated thyroid carcinoma (DTC) and in a group of patients treated for Hashimoto thyroiditis.
Design  Cross-sectional study.
Patients  We studied 154 patients with DTC treated with TSH suppressive thyroid hormone replacement therapy for longer than 3 years and 141 patients with Hashimoto thyroiditis treated for at least 6 months with T4.
Measurements  In all patients, serum levels of TSH, free T4, T3 and reverse T3 were measured and genotypes of the D2-Thr92Ala polymorphism were determined by Taqman assay. Univariate regression analysis was performed to determine the relation between T4 dosages and the D2-Thr92Ala polymorphism corrected for age, gender, BMI and serum TSH levels.
Results  Both in DTC patients and Hashimoto patients, no association was observed between serum thyroid hormone levels or T4 dosages in presence of the D2-Thr92Ala polymorphism. Categorization of DTC patients according to degree of TSH suppression did not change these results.
Conclusion  The D2-Thr92Ala polymorphism is not associated with thyroid hormone levels or T4 dose in patients treated for DTC or Hashimoto thyroiditis.